T Cell Activation: The importance of methionine metabolism
The immune system relies on a number of different cells types that work together to detect and clear unwanted infections from the body. T helper cells (also known as CD4+ T cells, and hereafter referred to as T cells) play an important role in this process as they modulate the activity of the immune cells that rid the body of infections. Antigens on the surface of infected cells can activate different subpopulations of T cells by binding to antigen-specific receptors on the surface of the T cells (Figure 1). Once activated, the T cells proliferate rapidly and work together to mediate the immune response against the antigen.
This rapid expansion of T cells is, however, metabolically taxing because DNA, proteins and other biomolecules have to be produced prior to every division of the cells. The synthesis of new proteins during this period relies on the T cells importing the essential amino acid methionine. In addition to its role in protein synthesis, methionine can also enter the 'methionine cycle' and be converted into s-adenosylmethionine (SAM), which provides methyl groups for numerous biochemical reactions.
SAM is a substrate for methyltransferase enzymes that are involved in the methylation of many different molecules (see Figure 1). The addition of a methyl group to a histone protein, for example, can alter gene transcription (Allis and Jenuwein, 2016); the methylation of other proteins influences processes such as signal transduction and metabolism (Murn and Shi, 2017); and the methylation of RNA can have a significant influence on gene expression (Zhao et al., 2017). Now, in eLife, Linda Sinclair and Doreen Cantrell, both at the University of Dundee, and co-workers at Dundee, Vanderbilt University and Duke University report that in addition to importing methionine for protein synthesis, activated T cells use it to generate the methyl groups needed for the methylation of DNA and RNA – processes that drive the differentiation and proliferation of T cells (Sinclair et al., 2019).
Using high-resolution mass spectrometry and metabolic labeling, Sinclair et al. showed that the activation of T cells by antigens led to a rapid upregulation of a methionine transporter called Slc7a5. The antigen activation of T cells also led to a marked increase in methyltransferases: however, the ability of these enzymes to methylate DNA, RNA or a protein depends on the availability of SAM. Since the expression of the enzymes that control the level of SAM do not change as a result of T cell activation, Sinclair et al. conclude that the import of methionine through Slc7a5 is the rate-limiting factor for the generation of methyl groups during T cell activation.
The expression of receptors for IL2 – a growth factor that drives proliferation of T cells – is also increased in response to antigen engagement with T cell receptors. Sinclair et al. observed that IL2 receptors were still upregulated even in the absence of methionine or the methionine transporter. This suggests that activation signals prepare cells to utilize extracellular methionine, but that the rapid upregulation of Slc7a5 and import of methionine is needed for the full activation of T cells.
Previous studies have shown that two other proteins – the protein kinase mTOR, which is involved ribosome biogenesis, protein translation and a number of other processes (Sabatini, 2017); and the transcription factor Myc – have important roles in regulating metabolism in T cells (Powell et al., 2012; MacIver et al., 2013), as does the upregulation of the nutrient transporters that import key metabolic building blocks such as glutamine and leucine. The fact that the activation of mTOR also enhances the expression of Myc and an amino acid transporter called CD98 illustrates the close connections between metabolic reprogramming and amino acid availability in immune cells (Wang et al., 2011; Sinclair et al., 2013). Sinclair et al. also showed that mTOR is partially dependent on the import of methionine to drive protein synthesis and fully activate the T cells.
It was also know that Slc7a5 imports leucine (in addition to importing methionine), and that the absence of either of these amino acids in the T cell leads to suboptimal activation of mTOR. It is possible that the need for multiple metabolites to support differentiation and proliferation may be a way of preventing T cells being activated when they should not be. Given recent advances in single-cell analysis it is conceivable that researchers might one day be able to measure changes in the epigenome (and also the transcriptome, proteome, acetylome and methylome) of T cells and combine these results with measurements of the flux through metabolic pathways to better understand the dynamic changes in T cells that underlie immune function. While aspects of the study by Sinclair et al. highlight the complexity of the metabolic reprogramming that T cells undergo during activation and differentiation, it also moves the field forward by establishing how the essential amino acid methionine supports T cell function. Precisely how levels of dietary methionine will contribute to methionine uptake by T cells – and whether those levels are modulated during infection, cancer or autoimmunity to influence T cell responses – is not yet known and will require further study.
References
-
The molecular hallmarks of epigenetic controlNature Reviews Genetics 17:487–500.https://doi.org/10.1038/nrg.2016.59
-
Metabolic regulation of T lymphocytesAnnual Review of Immunology 31:259–283.https://doi.org/10.1146/annurev-immunol-032712-095956
-
The winding path of protein methylation research: milestones and new frontiersNature Reviews Molecular Cell Biology 18:517–527.https://doi.org/10.1038/nrm.2017.35
-
Regulation of immune responses by mTORAnnual Review of Immunology 30:39–68.https://doi.org/10.1146/annurev-immunol-020711-075024
-
Post-transcriptional gene regulation by mRNA modificationsNature Reviews Molecular Cell Biology 18:31–42.https://doi.org/10.1038/nrm.2016.132
Article and author information
Author details
Publication history
Copyright
© 2019, Klein Geltink and Pearce
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,151
- views
-
- 593
- downloads
-
- 34
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Genetics and Genomics
- Immunology and Inflammation
PIK3R1 encodes three regulatory subunits of class IA phosphoinositide 3-kinase (PI3K), each associating with any of three catalytic subunits, namely p110α, p110β, or p110δ. Constitutional PIK3R1 mutations cause diseases with a genotype-phenotype relationship not yet fully explained: heterozygous loss-of-function mutations cause SHORT syndrome, featuring insulin resistance and short stature attributed to reduced p110α function, while heterozygous activating mutations cause immunodeficiency, attributed to p110δ activation and known as APDS2. Surprisingly, APDS2 patients do not show features of p110α hyperactivation, but do commonly have SHORT syndrome-like features, suggesting p110α hypofunction. We sought to investigate this. In dermal fibroblasts from an APDS2 patient, we found no increased PI3K signalling, with p110δ expression markedly reduced. In preadipocytes, the APDS2 variant was potently dominant negative, associating with Irs1 and Irs2 but failing to heterodimerise with p110α. This attenuation of p110α signalling by a p110δ-activating PIK3R1 variant potentially explains co-incidence of gain-of-function and loss-of-function PIK3R1 phenotypes.
-
- Immunology and Inflammation
Natural killer (NK) cells can control metastasis through cytotoxicity and IFN-γ production independently of T cells in experimental metastasis mouse models. The inverse correlation between NK activity and metastasis incidence supports a critical role for NK cells in human metastatic surveillance. However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors. Using a spontaneous metastasis mouse model of MHC-I+ breast cancer, we found that transfer of IL-15/IL-12-conditioned syngeneic NK cells after primary tumor resection promoted long-term survival of mice with low metastatic burden and induced a tumor-specific protective T cell response that is essential for the therapeutic effect. Furthermore, NK cell transfer augments activation of conventional dendritic cells (cDCs), Foxp3-CD4+ T cells and stem cell-like CD8+ T cells in metastatic lungs, to which IFN-γ of the transferred NK cells contributes significantly. These results imply direct interactions between transferred NK cells and endogenous cDCs to enhance T cell activation. We conducted an investigator-initiated clinical trial of autologous NK cell therapy in six patients with advanced cancer and observed that the NK cell therapy was safe and showed signs of effectiveness. These findings indicate that autologous NK cell therapy is effective in treating established low burden metastases of MHC-I+ tumor cells by activating the cDC-T cell axis at metastatic sites.